Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.45 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495364 | 1.00 | CCR2 (0.47) | CCR2MAOAKDM1AMAOBCYP3A4 | |
| SCHEMBL16839835 | 0.87 | ALDH1A1 (0.54) | CCR2MAOAKDM1AMAOBSSTR3 | |
| SCHEMBL4492918 | 0.86 | SCN9A (0.56) | CCR2TEAD1SCN9AP2RX7KDM4E | |
| SCHEMBL4490030 | 0.86 | SCN9A (0.56) | CCR2TEAD1SCN9AP2RX7KDM4E | |
| SCHEMBL14038227 | 0.86 | SSTR3 (0.56) | MAOAKDM1AMAOBSSTR3SCN9A | |
| SCHEMBL4735124 | 0.86 | SSTR3 (0.56) | MAOAKDM1AMAOBSSTR3SCN9A | |
| SCHEMBL4486701 | 0.86 | SSTR3 (0.56) | MAOAKDM1AMAOBSSTR3SCN9A | |
| SCHEMBL4481349 | 0.86 | SSTR3 (0.56) | MAOAKDM1AMAOBSSTR3SCN9A | |
| SCHEMBL4735123 | 0.86 | SSTR3 (0.56) | MAOAKDM1AMAOBSSTR3SCN9A | |
| SCHEMBL13896023 | 0.86 | SSTR3 (0.45) | SSTR3SCN9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2008073982-A2 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | CCR2 157/4885MAOA 1965/4885KDM1A 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.